In genetically engineered mouse models (GEMMs), EGFR-driven tumors express higher levels of PD-L1 with a more immunosuppressive tumor microenvironment (increased FoxP3+ T-cells, decreased CD8+/CD4+ ratio). This evidence concerns the gene CD8A and neoplasm.